Protocols: Indivior claims PhIII success, points to 2017 FDA OK; InVivo touts another patient response in spinal study
The UK’s Indivior (LON: INDV) got a boost today after announcing that its Phase III study of a monthly dose of buprenorphine was positive. The biotech says that based on its conversations with the FDA, the company may get a green light for this therapy by the end of next year. The monthly dosing is intended to assist patients who are being treated for opioid abuse, making a relapse less likely.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.